However, although phosphorylated tau (p-tau) levels are high in the brains of AD patients, cerebrospinal fluid p-tau levels are weakly associated with the pathological changes indicative of NFTs in the brains of AD patients (Buerger et al., 2006; Seppälä et al., 2012). The gene discussed is MAPT; the disease is Alzheimer disease.